Shares of Gtx Inc. (NASDAQ:GTXI) dropped 92.3 percent to $1.80 on Friday after a phase II trial found two doses of its sole clinical candidate, a selective androgen receptor modulator (SARM), failed to separate from placebo in helping postmenopausal women reduce stress urinary incontinence (SUI). The candidate, enobosarm, has been evaluated in 27 trials to date. Barring a compelling finding in the full data, the program will likely be wound down, Executive Chairman Rob Wills told BioWorld. The Gtx team will now turn its attention to identifying a lead from its preclinical selective androgen receptor degrader (SARD) program, he said.